News
Research from the School of Life Sciences hopes to accelerate the drug discovery process by providing key data that will aid in the design of new treatments to combat antimicrobial resistance (AMR).
News
Research from the School of Life Sciences hopes to accelerate the drug discovery process by providing key data that will aid in the design of new treatments to combat antimicrobial resistance (AMR).
Press release
Outstanding scientific research at the University of Dundee has been honoured by Scotland’s national academy
Press release
Some of Scotland’s brightest business prospects are preparing for an exciting future after being crowned winners of a major Scottish competition.
News
A collaboration between the research laboratories of Dr Mattie Pawlowic and Dr Susan Wyllie in the Wellcome Centre for Anti-Infectives Research at School of Life Sciences has generated a new tool that can be used for studying Cryptosporidium.
News
Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 55 years.
Impact case study
Shaping the future of commercial drug development and driving global pharmaceutical investment.
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.
News
Collaborative research between the Universities of Dundee and Cambridge has uncovered how ‘assassin’ immune cells are able keep on killing as they hunt down cancer cells, repeatedly reloading their toxic weapons.
Press release
A University of Dundee researcher is to join an international collaboration that brings scientists from academia together with one of the world’s largest pharma companies to help develop new drugs for cancer and other devastating diseases.
News
Collaborative research between scientists in the Division of Cell Signalling and Immunology and the University of Leeds has been published in eLife.
Press release
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
Press release
A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals.
Press release
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases.
Press release
Work to build on Dundee’s world-class expertise in biomedical sciences is set to begin in earnest after the ‘Growing the Tay Cities Biomedical Cluster’ project was officially signed off by the Tay Cities Region Joint Committee today (February 19).
Press release
A University of Dundee spinout company developing treatments for eczema, rheumatoid arthritis and other inflammatory conditions has completed its first round of private investment.
News
The o2h human health EIS Fund has announced its intention to lead an investment into In4Derm.
Press release
The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need.
Press release
Researchers at the University of Dundee are looking to transform pharmaceutical and cosmetics testing with their spinout venture that offers an alternative for many experiments currently only performed in animals.
News
The finalists for Converge 2020, Scotland’s leading academic company creation programme, have been announced with representation from the School included on the list with Dr Robyn Hickerson, Co-founder and Chief Scientific Officer of Ten Bio.
Press release
University of Dundee researchers hope to turn their spinout venture into a biotech company worth hundreds of millions of pounds by helping to treat people with eczema, rheumatoid arthritis and other inflammatory conditions.